

Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform



Specialized research sites that possess diverse therapeutic proficiencies and diverse patient populations play a pivotal role in effectively introducing novel drugs and treatments to the market. These sites provide comprehensive support services that encompass patient recruitment, regulatory adherence, and expedited data collection. By operating within condensed timelines, these facilities guarantee the streamlined execution of trials, and their adeptness proves invaluable for sponsors as they navigate the intricate pathways of clinical development. The contributions of these clinical research sites are paramount in propelling public health advancements on a worldwide level.

Since 2016 Monroe Biomedical Research (“MBR”) has built an expansive clinical

research database that is committed to diversity as a research priority. Their wholly dedicated research facility just outside of Charlotte, North Carolina hosts a study team with extensive clinical trial expertise, ranging from Phase I trials to high-volume bioequivalence studies. MBR’s white-glove service and commitment to diversity made it the ideal platform investment for New Harbor Capital to participate in the rapidly evolving clinical research site market.

Crosstree’s expertise in the clinical trial site industry (this being our third clinical trial site transaction of 2023) and deep understanding of MBR’s unique value proposition helped MBR identify New Harbor Capital as the ideal transaction partner for building out a more robust clinical research platform.

Crosstree helps clients by leveraging deep market expertise to identify the ideal partner that will maximize synergies and position the client to maximize its value.

ABOUT MONROE BIOMEDICAL RESEARCH



Monroe Biomedical Research is a facility wholly dedicated to clinical research and located near Charlotte, North Carolina. They are one of the highest enrolling research centers in the nation with a proven and scrutinized GCP record and a highly experienced study team.

ABOUT NEW HARBOR CAPITAL



New Harbor Capital is a Chicago-based private equity firm focused on investing in lower middle market, growth-oriented healthcare, education, and business services companies. Their Partners have over 90 years of combined experience, partnering with strong management teams to systematically enable accelerated growth in value creation. Since 2000, the New Harbor Partners have completed over 230 investments. As an experienced strategic partner, New Harbor supports management with ideas, connections, and resources to capitalize on growth potential.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON

Director

jason.layton@crosstreecapital.com

813-578-7109